Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024
Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.63. Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Good morning, and welcome to Sage Therapeutics First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only...
